Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: Finding the right balance in response to danger signals

Cailin Sibley, Raphaela Goldbach-Mansky

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Introduction: Interleukin-1 was the first cytokine identified and is a powerful inducer of fever and inflammation. The biologically active receptor for IL-1, shares signaling pathways with some pathogen recognition receptors, the Toll-like receptors (TLRs) which early on suggested an important role in innate immune function. Discussion: The discovery that some intracellular "danger receptors", the NOD like receptors (NLRs) can assemble to form multimolecular platforms, the inflammasomes, that not only sense intracellular danger but also activate IL-1β, has provided the molecular basis for the integration of IL-1 as an early response mediator in danger recognition. The critical role of balancing IL-1 production and signaling in human disease has recently been demonstrated in rare human monogenic diseases with mutations that affect the meticulous control of IL-1 production, release and signaling by leading to decreased or increased TLR/IL-1 signaling. In diseases of decreased TLR/IL-1 signaling (IRAK-4 and MyD88 deficiencies) patients are at risk for infections with gram positive organisms; and in diseases of increased signaling, patients develop systemic autoinflammatory diseases (cryopyrin-associated periodic syndromes (CAPS), and deficiency of the IL-1 receptor antagonist (DIRA)). Conclusion: Monogenic defects in a number of rare diseases that affect the balance of TLR/IL-1 signaling have provided us with opportunities to study the systemic effects of IL-1 in human diseases. The molecular defects in CAPS and DIRA provided a therapeutic rationale for targeting IL-1 and the impressive clinical results from IL-1 blocking therapies have undoubtedly confirmed the pivotal role of IL-1 in human disease and spurred the exploration of modifying IL-1 signaling in a number of genetically complex common human diseases.

Original languageEnglish (US)
Pages (from-to)210-222
Number of pages13
JournalClinical Immunology
Volume135
Issue number2
DOIs
StatePublished - May 2010
Externally publishedYes

Fingerprint

Interleukin-1
Toll-Like Receptor 1
Interleukin-1 Receptors
Cryopyrin-Associated Periodic Syndromes
Inflammasomes
Toll-Like Receptors
Rare Diseases
Fever
Cytokines
Inflammation

Keywords

  • Anakinra
  • Autoinflammatory diseases
  • DIRA
  • Genetic disease
  • IL-1
  • IL-1Ra
  • IL1RN
  • Neonatal disorder
  • NLRP3
  • NOD like receptors
  • NOMID/CINCA

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes : Finding the right balance in response to danger signals. / Sibley, Cailin; Goldbach-Mansky, Raphaela.

In: Clinical Immunology, Vol. 135, No. 2, 05.2010, p. 210-222.

Research output: Contribution to journalReview article

@article{c5ac928015524b3db8750046cfd7ad0a,
title = "Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: Finding the right balance in response to danger signals",
abstract = "Introduction: Interleukin-1 was the first cytokine identified and is a powerful inducer of fever and inflammation. The biologically active receptor for IL-1, shares signaling pathways with some pathogen recognition receptors, the Toll-like receptors (TLRs) which early on suggested an important role in innate immune function. Discussion: The discovery that some intracellular {"}danger receptors{"}, the NOD like receptors (NLRs) can assemble to form multimolecular platforms, the inflammasomes, that not only sense intracellular danger but also activate IL-1β, has provided the molecular basis for the integration of IL-1 as an early response mediator in danger recognition. The critical role of balancing IL-1 production and signaling in human disease has recently been demonstrated in rare human monogenic diseases with mutations that affect the meticulous control of IL-1 production, release and signaling by leading to decreased or increased TLR/IL-1 signaling. In diseases of decreased TLR/IL-1 signaling (IRAK-4 and MyD88 deficiencies) patients are at risk for infections with gram positive organisms; and in diseases of increased signaling, patients develop systemic autoinflammatory diseases (cryopyrin-associated periodic syndromes (CAPS), and deficiency of the IL-1 receptor antagonist (DIRA)). Conclusion: Monogenic defects in a number of rare diseases that affect the balance of TLR/IL-1 signaling have provided us with opportunities to study the systemic effects of IL-1 in human diseases. The molecular defects in CAPS and DIRA provided a therapeutic rationale for targeting IL-1 and the impressive clinical results from IL-1 blocking therapies have undoubtedly confirmed the pivotal role of IL-1 in human disease and spurred the exploration of modifying IL-1 signaling in a number of genetically complex common human diseases.",
keywords = "Anakinra, Autoinflammatory diseases, DIRA, Genetic disease, IL-1, IL-1Ra, IL1RN, Neonatal disorder, NLRP3, NOD like receptors, NOMID/CINCA",
author = "Cailin Sibley and Raphaela Goldbach-Mansky",
year = "2010",
month = "5",
doi = "10.1016/j.clim.2010.02.013",
language = "English (US)",
volume = "135",
pages = "210--222",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes

T2 - Finding the right balance in response to danger signals

AU - Sibley, Cailin

AU - Goldbach-Mansky, Raphaela

PY - 2010/5

Y1 - 2010/5

N2 - Introduction: Interleukin-1 was the first cytokine identified and is a powerful inducer of fever and inflammation. The biologically active receptor for IL-1, shares signaling pathways with some pathogen recognition receptors, the Toll-like receptors (TLRs) which early on suggested an important role in innate immune function. Discussion: The discovery that some intracellular "danger receptors", the NOD like receptors (NLRs) can assemble to form multimolecular platforms, the inflammasomes, that not only sense intracellular danger but also activate IL-1β, has provided the molecular basis for the integration of IL-1 as an early response mediator in danger recognition. The critical role of balancing IL-1 production and signaling in human disease has recently been demonstrated in rare human monogenic diseases with mutations that affect the meticulous control of IL-1 production, release and signaling by leading to decreased or increased TLR/IL-1 signaling. In diseases of decreased TLR/IL-1 signaling (IRAK-4 and MyD88 deficiencies) patients are at risk for infections with gram positive organisms; and in diseases of increased signaling, patients develop systemic autoinflammatory diseases (cryopyrin-associated periodic syndromes (CAPS), and deficiency of the IL-1 receptor antagonist (DIRA)). Conclusion: Monogenic defects in a number of rare diseases that affect the balance of TLR/IL-1 signaling have provided us with opportunities to study the systemic effects of IL-1 in human diseases. The molecular defects in CAPS and DIRA provided a therapeutic rationale for targeting IL-1 and the impressive clinical results from IL-1 blocking therapies have undoubtedly confirmed the pivotal role of IL-1 in human disease and spurred the exploration of modifying IL-1 signaling in a number of genetically complex common human diseases.

AB - Introduction: Interleukin-1 was the first cytokine identified and is a powerful inducer of fever and inflammation. The biologically active receptor for IL-1, shares signaling pathways with some pathogen recognition receptors, the Toll-like receptors (TLRs) which early on suggested an important role in innate immune function. Discussion: The discovery that some intracellular "danger receptors", the NOD like receptors (NLRs) can assemble to form multimolecular platforms, the inflammasomes, that not only sense intracellular danger but also activate IL-1β, has provided the molecular basis for the integration of IL-1 as an early response mediator in danger recognition. The critical role of balancing IL-1 production and signaling in human disease has recently been demonstrated in rare human monogenic diseases with mutations that affect the meticulous control of IL-1 production, release and signaling by leading to decreased or increased TLR/IL-1 signaling. In diseases of decreased TLR/IL-1 signaling (IRAK-4 and MyD88 deficiencies) patients are at risk for infections with gram positive organisms; and in diseases of increased signaling, patients develop systemic autoinflammatory diseases (cryopyrin-associated periodic syndromes (CAPS), and deficiency of the IL-1 receptor antagonist (DIRA)). Conclusion: Monogenic defects in a number of rare diseases that affect the balance of TLR/IL-1 signaling have provided us with opportunities to study the systemic effects of IL-1 in human diseases. The molecular defects in CAPS and DIRA provided a therapeutic rationale for targeting IL-1 and the impressive clinical results from IL-1 blocking therapies have undoubtedly confirmed the pivotal role of IL-1 in human disease and spurred the exploration of modifying IL-1 signaling in a number of genetically complex common human diseases.

KW - Anakinra

KW - Autoinflammatory diseases

KW - DIRA

KW - Genetic disease

KW - IL-1

KW - IL-1Ra

KW - IL1RN

KW - Neonatal disorder

KW - NLRP3

KW - NOD like receptors

KW - NOMID/CINCA

UR - http://www.scopus.com/inward/record.url?scp=77950630298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950630298&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2010.02.013

DO - 10.1016/j.clim.2010.02.013

M3 - Review article

C2 - 20353899

AN - SCOPUS:77950630298

VL - 135

SP - 210

EP - 222

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -